RecruitingPhase 4NCT04731155

Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction

Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium

Sponsor

Shanghai Tong Ren Hospital

Enrollment

20 participants

Start Date

Apr 12, 2021

Study Type

INTERVENTIONAL

Conditions

Early PCSK9 Inhibitor on Ventricular Remodling

Summary

This is a prospect, multi-center, random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after primary percutaneous intervention(PPCI). Totally,twenty acute myocardium infarction subjects will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy for AMI including PPCI. The experiment group will receive first PCSK9 inhibitor before PPCI, then twice a month until 3 months later. Six month after AMI, Myocardial salvage index will be used to evaluate ventricular remodeling. TnI peaking time and LDL control rates also will be recorded and compared.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called PCSK9 inhibitor （Alirocumab）plus standard medications and a drug called standard medications for people with early pcsk9 inhibitor on ventricular remodling. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPCSK9 inhibitor （Alirocumab）plus standard medications

PCSK9 inhibitor（Alirocumab） was giving to subjects before PPCI and continued twice a month until 3 month after AMI

DRUGstandard medications

standard medications was giving to subjects according guidelines

Locations(2)

Tongren Hospital, Shanghai

Shanghai, Shanghai Municipality, China

Shanghai tenth people's hospital

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04731155